- Home
- SJT vs NNNN Comparison
SJT vs NNNN Comparison
Compare SJT & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | NNNN |
|---|---|---|
| Founded | 1980 | 2021 |
| Country | United States | Germany |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 163.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | SJT | NNNN |
|---|---|---|
| Price | $3.28 | $3.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 376.1K | 46.5K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.37 | $3.09 |
| 52 Week High | $6.55 | $44.73 |
Technical Indicators
Market Signals| Indicator | SJT | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 31.74 |
| Support Level | $2.68 | $3.09 |
| Resistance Level | $3.27 | $6.95 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 7.55 | 36.43 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).